DYAI Dyadic International, Inc.
USHealthcareAs of 2026-07-10 16:00
Why DYAI matters now
Dyadic International, Inc. (DYAI) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.06 with -0.93% on the session and $38.6M in market capitalization; recent performance reads 1-month +8.46% and YTD -16.81%.
The latest financial table shown here is Q1 2026, with revenue of $1.1M, net income of $-2.0M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -20.1%.
The latest indexable market news headline is "Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.00; recent insider activity includes EMALFARB MARK A filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-69.81
P/S
9.58
EV/EBITDA
-4.14
DCF Value
$-0.29
FCF Yield
-20.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
31.3%
Operating Margin
-238.4%
Net Margin
-245.1%
ROE
-1005.0%
ROA
-93.4%
ROIC
-152.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.1M | $-2.0M | $-0.05 |
| Q4 2025 | $235.7K | $-1.6M | $-0.04 |
| FY 2025 | $1.2M | $-7.4M | $-0.23 |
| Q3 2025 | $1.2M | $-2.0M | $-0.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$3.00 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.16
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.